The Dermatology Digest

JANUARY 2, 2024

Dennis Gross Skincare is the perfect complement to our global portfolio of prestige brands as their core values are aligned with ours in terms of their scientific and innovative approach to beauty and our people-first culture.” Meet Spiderwort’s CelluJuve Clinical Advisory Board Spiderwort Inc.

Dermatology 36

Dermatology Sales Skincare Portfolios 36

Spa Executive

AUGUST 27, 2024

Roger Sholanki, Book4Time Founder and Chief Executive Officer, commented, “Over the past 20 years, we have worked hand-in-hand with the world’s leading hospitality brands in over 100 countries to develop the industry’s #1 SaaS platform for spa and wellness operations.

Management 52

Management Hospital Technology Sales 52

Spa Executive

OCTOBER 23, 2024

Travelers don’t just want to choose their own adventure – they want to maximize every moment of their time away,” said Chris Nassetta, president and chief executive officer, Hilton. Hilton’s 2025 Trends Report unveils the rising travel trends predicted to ignite conversation and innovation while reshaping the travel experience in 2025.

Portfolios 52

Portfolios Technology Social Media Branding 52

The Dermatology Digest

OCTOBER 1, 2024

“We are encouraged by the outcome from the recent FDA meeting and the opportunity to advance our development of prabotulinumtoxinA utilizing the 351(k) biosimilar regulatory pathway,” says Marc Forth, AEON’s President and Chief Executive Officer, in a news release. “We

Hydration 36

Hydration Portfolios Office Surgery 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

MARCH 5, 2024

Chief Executive Officer of Apogee, in a news release. “We are excited to embark on the next phase of development for APG777, with plans to initiate our Phase 2 clinical trial in the first half of this year while rapidly progressing the rest of our pipeline forward.

Injections 36

Injections Safety Sustainability Clinic 36

Aesthetics Advisor

SEPTEMBER 15, 2023

It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutations we tested ,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed.

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

APRIL 16, 2025

With the introduction of Evolysse, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 71

Injections Portfolios Innovations Technology 71

Spa Industry Association

MARCH 20, 2025

Innovative Skincare Pioneer Expands to 40 Premier Woodhouse Spa Locations, Elevating Signature Services and Wellness at Home LOS ANGELES, CALIF. KNESKOs presence has grown from three pilot locations, to 40 spas in the Woodhouse Spa portfolio.

Partnerships 52

Partnerships Portfolios Innovations Office 52

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 73

Injections Portfolios Innovations Safety 73